The Novel β‐lactamase Inhibitor Enmetazobactam is More Potent than Tazobactam against ESBL‐producing Enterobacteriaceae

Thursday September 05, 2019

Pharmacodynamic Targets of Enmetazobactam, Combined with Cefepime, Against ESBL‐Producing Isolates of K. pneumoniae in a Murine Thigh Infection Model

Thursday September 05, 2019

The Exposure‐Response Relationship of Enmetazobactam, Combined with Cefepime, Is Best Described by fT > CT in a Murine Thigh Infection Model

Thursday September 05, 2019

Proposed cefepime-AAI101 (30/20 ug) and cefepime (30 ug) disk diffusion quality control ranges using a CLSI M23 (2018) multi-laboratory study design

Michael D. Huband1, Kelley A. Fedler1, Amy A. Watters1, A Belley2, Philipp Knechtle2, Robert K. Flamm1 1 JMI Laboratories North Liberty, Iowa, USA; 2 Allecra Therapeutics SAS, Saint-Louis, France

29th ECCMID 2019, Amsterdam, The Netherlands

In vitro activity of the extended-spectrum beta-lactamase inhibitor AAI101, in combination with cefepime, against 90 molecularly characterized Enterobacteriaceae isolates expressing a variety of non-beta-lactam resistance mechanisms

Michael D. Huband1, Amy A. Watters1, Jill M. Lindley1, Lalitagauri M. Deshpande1, A Belley2, Philipp Knechtle2, Robert K. Flamm1 1 JMI Laboratories North Liberty, Iowa, USA; 2 Allecra Therapeutics SAS, Saint-Louis, France

29th ECCMID 2019, Amsterdam, The Netherlands

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016

MD Huband1, PR Rhomberg1, KA Fedler1, RK Flamm1, P Knechtle2, S Shapiro2, 1 JMI Laboratories, Inc., 2 Allecra Therapeutics SAS ASM Microbe 2018, Las Vegas

29th ECCMID 2019, Amsterdam, The Netherlands

In Vitro Activity of Cefepime-AAI101 towards Burkholderia mallei

Samandra T. Demons 1, Jeremy R. Hershfield 1, Lynda L. Miller 1, Stefanie A. Halasohoris 1 and Stuart Shapiro 2, 1 United States Army Medical Research Institute of Infectious Diseases 2 Allecra Therapeutics SAS

ASM Biothreats 2018, Baltimore

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101

MD Huband1, PR Rhomberg1, KA Fedler1, RK Flamm1, P Knechtle,2 S Shapiro21 JMI Laboratories, Inc., North Liberty, Iowa, USA; 2 Allecra Therapeutics SAS, F-68300 Saint-Louis, France

28th ECCMID 2018, Madrid, Spain

Activity of the novel extended-spectrum beta-lactamase inhibitor AAI101 in Combination with cefepime against Enterobacteriaceae collected from US and European hospitals during 2014/2015

I. Morrissey1, S. Magnet1, S. Hawser1, S. Shapiro21IHMA Europe Sàrl, Monthey, Switzerland , 2Allecra Therapeutics, St-Louis, France

28th ECCMID 2018, Madrid, Spain

Activity of a novel extended-spectrum beta-lactamase inhibitor, AAI101, combined with cefepime against beta-lactamase-producing Enterobacteriaceae in a murine septicaemia model

Cédric Jacqueline,1,2Gilles Potel,1,2Jocelyne Caillon,1,2Amokrane Reghal,2& Stuart Shapiro31EA 3826 (Thérapeutiques Anti-Infectieuses), IRS2 Nantes -Biotech, Université de Nantes, France2Atlangram, IRS2 Nantes -Biotech, Nantes, France 3Allecra Therapeutics SAS, F-68300 Saint-Louis, France

28th ECCMID 2018, Madrid, Spain

Cefepime-AAI101 and cefepime MIC quality-control ranges using a CLSI M23-A4 multi-laboratory study design

MD Huband1, S Shapiro2, KA Fedler1, RK Flamm11JMI Laboratories, North Liberty, Iowa, USA; 2Allecra Therapeutics, Saint-Louis, France

28th ECCMID 2018, Madrid, Spain

Activity of a novel extended-spectrum beta-lactamase inhibitor, AAI101, combined with cefepime against beta-lactamase-producing Enterobacteriaceae in a neutropenic murine pneumonia model

P. Warn,1R. Odedra,1J. Gould,1P. Knechtle,2*& S. Shapiro21Evotec (UK) Ltd., Alderley Park, UK 2Allecra Therapeutics SAS, Saint-Louis, France

28th ECCMID 2018, Madrid, Spain

In vitro activities of AAI101, a novel extended-spectrum beta-lactamase inhibitor, and tazobactam, in combination with cefepime, against extended-spectrum beta-lactamase producing Klebsiella pneumoniae clinical isolates

I. Morrissey,1S. Magnet,1S. Hawser,1C. De Piano,1S. Shapiro,2& Philipp Knechtle21IHMA Europe Sàrl, Monthey, Switzerland, 2Allecra Therapeutics, St-Louis, France

28th ECCMID 2018, Madrid, Spain

Activityof the novel extended-spectrum β-lactamase inhibitor AAI101 in combination with cefepimetowards a challenge panel of Acinetobacter baumannii

I. Morrissey1, S. Magnet1, S. Hawser1, P. G. Higgins2, H. Seifert2, & S. Shapiro31IHMA Europe Sàrl, Monthey, Switzerland 2Institute for Medical Microbiology, Immunology & Hygiene, University of Cologne, Germany 3Allecra Therapeutics, St-Louis, France

ID Week 2017 San Diego

AAI101, a novel beta-lactamase inhibitor: microbiological and enzymatic profiling

Krisztina M. Papp-Wallace1,2,Christopher R. Bethel1, Melissa D. Barnes1,2, Joseph D. Rutter1, Magdalena A. Taracila1,2, Saralee Bajaksouzian2,3, Michael R. Jacobs2,3, and Robert A. Bonomo1,2 Louis Stokes Cleveland VAMC1, Case Western Reserve University2, and University Hospitals3, Cleveland, OH USA

ID Week 2017 San Diego

In vitro activity of cefepime-AAI101 vs. drug-resistant Klebsiella pneumoniae clinical isolates

Y. Carmeli1, Amos Adler1, EleonorRashi1, R. Pypstra2, & S. Shapiro21Tel Aviv SouraskyMedical Center, Tel Aviv, Israel; 2Allecra Therapeutics SAS, St-Louis, France

26th ECCMID 2016, Amsterdam, The Netherlands

Pharmacodynamic evaluation of AAI101, a novel extended-spectrum beta-lactamase inhibitor (BLI), with piperacillin against ESBL producers in a hollow fiber infection model

A. Louie,1 S. Kurhanewicz,1 N. Robbins,1 W. Liu,1 S. Fikes,1 D. Brown,1 S. Shapiro,2 R. Pypstra,2 and G.L. Drusano.1Inst. for Therapeutic Innovation, Univ. of Florida, Orlando, FL1 & Allecra Therapeutics SAS, St-Louis, France.2

55th ICCAC 2015, San Diego

• Comparative Efficacy of Human Simulated Exposures of Cefepime and Cefepime/AAI101 against Clinical Multidrug-Resistant Enterobacteriaceae • Safety, Tolerability and Pharmacokinetics of AAI101, and Extended-Spectrum β-Lactamase Inhibitor, in Healthy Adult Males

Jared L. Crandon, PharmD, BCPS1and David P. Nicolau, PharmD, FCCP, FIDSA1, 21Center for Anti-Infective Research and Development, Hartford, Connecticut; 2Department of Medicine, Division of Infectious Diseases Hartford Hospital, Hartford, Connecticut, USA

54th ICAAC 2014, Washington, DC

Characterization Of Beta-Lactamase Inhibition By Aai101, An Extended Spectrum Beta-Lactamase Inhibitor

P. Nordmann,1D. Girlich,2N. Benedict,3R. Pypstra,3& S. Shapiro31Dept Medicine, University of Fribourg, Switzerland; 2INSERM Unit 914, HôpitalBicetre, Paris, France; 3Allecra Therapeutics SAS, St-Louis, France

24th ECCMID 2014, Barcelona, Spain

Efficacy Of Extended Spectrum Beta-Lactamase Inhibitor Aai101 Combined With Beta-Lactams In Murine Models Of Systemic Gram-Negative Infection

M. Paul-Satyaseela,1K. Koppolu,1U. P. Senthilkumar,1& S. Shapiro21Orchid Chemicals & Pharmaceuticals, Ltd., Chennai, India; 2AllecraTherapeutics SAS, St-Louis, France

24th ECCMID 2014, Barcelona, Spain

In-Vitro Activity Of Aai101, A New Beta-Lactamase Inhibitor, Combined With Beta lactam Antibiotics Against A Challenge Panel Of Beta-Lactam-Resistant Gram-negative Clinical Isolates

S. Mushtaq,1A. Chaudhry,1R. Adkin,1N. Woodford,1N. Benedict,1R. Pypstra,2and S. Shapiro21Antimicrobial Resistance & Healthcare Associated Infections Reference Unit, Public Health England, UK; 2Allecra Therapeutics SAS, St-Louis, France

24th ECCMID 2014, Barcelona, Spain